OncoMatch/Clinical Trials/NCT06555003
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
Is NCT06555003 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Drug-Eluting Embolic Bead and Chemotherapy drug for liver neoplasm.
Treatment: Drug-Eluting Embolic Bead · Chemotherapy drug — A total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group (systemic chemotherapy alone). After 4 cycles of chemotherapy and 2 cycles of DEBIRI, patient reassessment to evaluate treatment response, based on RECIST criteria, will be performed using MRI or CT scan within 1-3 months of treatment initiation. The feasibility of secondary tumor resection, as primary endpoint, will be reassessed at a three-month follow-up multidisciplinary team (MDT) meeting, guided by established clinical guidelines.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/l, platelet ≥ 75 ×10^9/l, international normalized ratio ≤ 1.3
Kidney function
creatinine ≤ 2.0 mg/dl
Liver function
total bilirubin ≤ 2.0 mg/dl, aspartate aminotransferase and alanine aminotransferase ≤ 5 × uln, albumin ≥ 2.5 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify